Brief: Biomarin Provides Update On Phase 3 Trial For Bmn 401 In Children Aged 1-12 With Enpp1 Deficiency

BioMarin Pharmaceutical

18/05/2026 14:47

May 18 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O:

BIOMARIN PROVIDES UPDATE ON PHASE 3 TRIAL FOR BMN 401 IN CHILDREN AGED 1-12 WITH ENPP1 DEFICIENCY

BIOMARIN PHARMACEUTICAL INC - ENERGY 3 STUDY MEETS 1 OF 2 CO-PRIMARY ENDPOINTS IN ENPP1 DEFICIENCY

BIOMARIN PHARMACEUTICAL INC - BMN 401 SHOWS SIGNIFICANT INCREASE IN PLASMA INORGANIC PYROPHOSPHATE IN ENERGY 3 STUDY

BIOMARIN PHARMACEUTICAL INC - NO IMPROVEMENT IN RADIAGRAPHIC GLOBAL IMPRESSION OF CHANGE SCORES IN ENERGY 3 STUDY

BIOMARIN PHARMACEUTICAL INC - BMN 401 GENERALLY WELL-TOLERATED WITH NO NEW SAFETY SIGNALS REPORTED

BIOMARIN PHARMACEUTICAL INC - NO POSITIVE TRENDS IN SECONDARY ENDPOINTS INCLUDING RICKETS SEVERITY SCORE AND GROWTH Z-SCORE

BIOMARIN PHARMACEUTICAL INC - EVALUATING DATA TO DETERMINE NEXT STEPS FOR BMN 401

Source text: ID:nPnbLh8Tza

Further company coverage: BMRN.O

 ((Reuters.Briefs@thomsonreuters.com;))